

# Optimization of PSA Screening Policies: A Comparison of the Patient and Societal Perspectives

Jingyu Zhang, PhD, Brian T. Denton, PhD, Hari Balasubramanian, PhD,  
Nilay D. Shah, PhD, Brant A. Inman, MD

---

**Objective.** To estimate the benefit of PSA-based screening for prostate cancer from the patient and societal perspectives. **Method.** A partially observable Markov decision process model was used to optimize PSA screening decisions. Age-specific prostate cancer incidence rates and the mortality rates from prostate cancer and competing causes were considered. The model trades off the potential benefit of early detection with the cost of screening and loss of patient quality of life due to screening and treatment. PSA testing and biopsy decisions are made based on the patient's probability of having prostate cancer. Probabilities are inferred based on the patient's complete PSA history using Bayesian updating. **Data Sources.** The results of all PSA tests and biopsies done in Olmsted County, Minnesota, from 1993 to 2005 (11,872 men and 50,589 PSA test results). **Outcome Measures.** Patients' perspective: to maximize expected quality-adjusted life years (QALYs); societal perspective: to maximize the expected monetary value based on societal

willingness to pay for QALYs and the cost of PSA testing, prostate biopsies, and treatment. **Results.** From the patient perspective, the optimal policy recommends stopping PSA testing and biopsy at age 76. From the societal perspective, the stopping age is 71. The expected incremental benefit of optimal screening over the traditional guideline of annual PSA screening with threshold 4.0 ng/mL for biopsy is estimated to be 0.165 QALYs per person from the patient perspective and 0.161 QALYs per person from the societal perspective. PSA screening based on traditional guidelines is found to be worse than no screening at all. **Conclusions.** PSA testing done with traditional guidelines underperforms and therefore underestimates the potential benefit of screening. Optimal screening guidelines differ significantly depending on the perspective of the decision maker. **Keywords:** prostate cancer; PSA; partially observable Markov decision process; patient perspective; societal perspective. (*Med Decis Making XXXX;XX:xx-xx*)

---

---

Received 20 July 2010 from Philips Research North America, Briarcliff Manor, NY (JZ); Edward P. Fitts Department of Industrial & Systems Engineering, North Carolina State University, Raleigh, NC (BTD); Department of Mechanical & Industrial Engineering, University of Massachusetts, Amherst, MA (HB); Division of Health Care Policy and Research, Mayo Clinic, Rochester, MN (NDS); and Department of Surgery, School of Medicine, Duke University, Durham, NC (BAI). This work was presented in poster sessions at SMDM 31st Annual Meeting. Financial support for this study was provided partly by grant CMMI 0844511 from the National Science Foundation. The funding agreement ensured the authors' independence in designing the study, interpreting the data, writing, and publishing the report. This work was done when Jingyu Zhang was a PhD student at North Carolina State University. Revision accepted for publication 25 May 2011.

Address correspondence to Jingyu Zhang, PhD, Philips Research North America, Briarcliff Manor, NY 10510; e-mail: jingyu.zhang@philips.com

DOI: 10.1177/0272989X11416513

PSA testing is controversial because of poor sensitivity and specificity of the test<sup>1</sup> and the concern of overdiagnosis.<sup>2,3</sup> Patients with higher than normal PSA values have a greater risk of prostate cancer. However, a patient's PSA varies in a continuous range, and higher than normal levels may occur for a variety of other reasons. The imperfect sensitivity of PSA tests can result in harm to patients. For instance, if a patient's PSA test result is incorrectly classified as suspicious, he will receive an unnecessary biopsy. In addition to providing imperfect information (sensitivity of 80%<sup>4</sup>), biopsies are painful and carry the possibility of side-effects such as cramping, bleeding, and infection. Furthermore, some patients detected with prostate cancer who receive treatment will ultimately die from other causes. The decision whether and when to perform a PSA test and whether to refer

a patient for biopsy must trade off the potential benefits from early detection, the side effects of biopsy and subsequent treatment, and the costs of PSA tests, biopsies, and treatments because of overdiagnosis.

Many family physicians and urologists in the United States use PSA tests to screen their patients, commonly initiating annual screening at age 50.<sup>5</sup> However, recently some have suggested that PSA screening should not be done routinely because it results in unnecessary biopsies, potential harm, and increased treatment costs.<sup>6–10</sup> In 2009, the U.S. Preventive Services Task Force recommended a guideline for prostate cancer screening, stating that people older than 75 years should not be screened.<sup>11</sup> The guideline made no specific recommendation for people younger than 75 years, citing insufficient evidence. A guideline from the American Urological Association<sup>8</sup> recommends starting PSA screening at age 40 and then determining future screening intervals based on previous results. However, no specific direction on how to use previous results is provided.

The debate on the controversy of PSA screening continues between 2 large clinical trials reported in 2009. The U.S. Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial<sup>12</sup> concluded that screening does not reduce mortality. On the other hand, the European Randomized Study of Screening for Prostate Cancer trial<sup>10</sup> found that the PSA-based screening reduced prostate cancer mortality by approximately 20%. However, the 2 trials used 2 different PSA screening frequencies and thresholds for biopsy. Furthermore, concerns have been expressed about bias in the U.S. PLCO trial.<sup>13,14</sup>

We use a population-based model to investigate prostate cancer screening policies. We consider the patient's perspective, measured in expected quality-adjusted life years (QALYs), and the societal perspective, measured as the difference in rewards for QALYs and the total cost of PSA tests, biopsies, and treatment over the patient's lifetime. We present empirical results for the optimal age-dependent prostate cancer screening policy based on a population from Olmsted County, Minnesota. The optimal screening policy is compared with a commonly used PSA screening policy to estimate the potential benefit gain from considering all PSA tests in the patient's history. Finally, the implied stopping time for PSA screening is contrasted for the patient and societal perspectives.

## METHODS

We formulate a partially observable Markov decision process (POMDP) model for the prostate cancer

screening problem. The true health states in our model are not directly observable but can be probabilistically inferred from the patient's PSA history. Our POMDP model is described as follows. One criterion in our model, from the patient's perspective, is to maximize the expected QALYs. QALYs are estimated by decrementing a normal life year based on (a) occurrence of biopsy, (b) treatment upon detection of cancer, and (c) long-term complications resulting from treatment. The optimal policy obtained from solving the POMDP trades off the long-term benefits from early detection of prostate cancer with the short-term negative impact of biopsy and long-term side effects of treatment. The second criterion in our model, from the societal perspective, is to maximize the expected monetary value, using the societal willingness to pay to translate the expected QALYs into a monetary value and subtracting the costs of PSA tests, biopsies, and treatments.

In our model, patients progress through the following unobservable health states before cancer is diagnosed: no prostate cancer, organ-confined prostate cancer, extracapsular prostate cancer, lymph node-positive prostate cancer, metastasis, and death. The patient's health state is inferred probabilistically based on PSA test observations. Observations are defined by a set of clinically relevant ranges  $\{[0, 1), [1, 2.5), [2.5, 4), [4, 7), [7, 10), \text{and } [10, \infty)\}$ . At each annual decision epoch, there is a 2-stage decision problem: The first stage is whether to PSA test; the second stage is whether to biopsy. If a patient receives a positive biopsy result, he is assumed to be treated by prostatectomy. If a patient receives a negative biopsy result, then he awaits PSA screening in the next decision epoch. Figure 1 is an illustration of the prostate cancer screening decision process.

Following is a description of the essential elements of the POMDP model (additional details are in the appendix):

*Time Horizon:* PSA screening is performed at each of a set of annual decision epochs starting at age 40,  $t \in \{40, 41, 42, \dots\}$ .

*Decisions:*  $a_t \in \{B, DB, DP\}$ , denotes the decision to perform a biopsy (B), defer biopsy and obtain a new PSA test result in epoch  $t+1$  (DB), or defer the biopsy decision and PSA testing in decision epoch  $t+1$  (DP). Combinations of these 3 actions over the decision horizon determine the PSA test and biopsy schedule. For instance,  $a_{40} = DB$ ,  $a_{41} = DP$ ,  $a_{42} = DB$ , and  $a_{43} = B$  imply PSA testing at age 41 and 43, followed by biopsy at age 43. Note that decisions are




Figure 1 Recurring screening decision process for prostate cancer screening, in which decision epochs ( $t, t+1, \dots$ ) occur annually. Squares represent decisions; circles represent test observations; the triangle denotes the expected outcome upon detection of prostate cancer.

made sequentially and based on the probability of prostate cancer at each decision epoch.

**States:** At each decision epoch a patient is in one of several health states including no cancer (NC), organ-confined (OC) cancer detected, extraprostatic (EP) cancer detected, lymph node-positive (LN) cancer detected, metastases (mets) detected, and death from prostate cancer and all other causes ( $D$ ). Prior to detection, OC, EP, LN, and mets are not differentiable. We use an aggregate state  $C$  to denote prostate cancer present but not detected. Note that we assume states  $NC$  and  $C$  are not directly observable without biopsy. The underlying health states of Markov model are illustrated in Figure 2.

**Observations:** At each decision epoch the patient is observed in 1 of a set of observable states including a particular PSA interval, or cancer detected and treated ( $T$ ) or death ( $D$ ). The observable states are indexed by  $\ell_t \in M = \{1, 2, 3, \dots, m, T, D\}$ .

**Transition probabilities:** There are 2 kinds of transition probabilities in the model:  $p_t(s_{t+1}|s_t, a_t)$  denote the state transition probability from health state  $s_t$  to  $s_{t+1}$  at epoch  $t$  given action  $a_t$ .  $q_t(\ell_t|s_t)$  denote the probability of observing PSA state  $\ell_t \in M$  given the patient is in health state  $s_t \in S$ ; its matrix form is also known as the information matrix.

**Belief States:** The belief state,  $\pi_t = (\pi_t(NC), \pi_t(C), \pi_t(T), \pi_t(D))$ , defines the probability the patient is in

1 of the 4 health states at epoch  $t$ . Note that for a patient without a positive biopsy result, his belief state can be represented as  $\pi_t = (1 - \pi_t(C), \pi_t(C), 0, 0)$ . We use  $\pi_t(C)$ , the probability of having prostate cancer, to denote the belief state in the remainder of the article.

**Rewards:**  $r_t(s_t, a_t)$  is the reward of living for a year given the patient is in health state  $s_t$  and decision  $a_t$ . The expected reward of living for a year is the average over possible health states:  $r_t(\pi_t, a_t) = \sum_{s_t \in S} r_t(s_t, a_t) \pi_t(s_t)$ . The reward defines the decision maker's perspective. For the patient's perspective, it is measured in QALYs. For the societal perspective, it is measured (in dollars) as the difference in (a) the product of QALYs and a willingness to pay factor and (b) the cost of PSA tests, biopsy, and treatment.

We assume that a patient has at most 1 biopsy prior to detection of prostate cancer. This is a reasonable assumption because multiple biopsies prior to detection are seldom done given the invasive nature of the procedure and the slow progression of prostate cancer. This assumption is validated by our data set, in which 81.4% of the patients have only 1 biopsy. It is also consistent with findings in Reference 15 in the context of regular annual screening.




Figure 2 Transitions among health states of the prostate cancer Markov model. Note that death from other causes is possible for any health state in our model but is omitted for simplicity.

The detailed transition probabilities, the reward function, and the optimality equations for the POMDP are provided in the appendix. The optimal screening policy is obtained by solving the optimality equations to estimate the PSA screening and biopsy that maximize the expected rewards over a patient’s lifetime. POMDPs are computationally challenging to solve. We use a finite fixed-grid method (Reference 16) to solve the optimality equations and obtain the optimal policy. Theoretical properties and methodological details of the solution methodology for a related model on biopsy referral can be found in Reference 15.

The optimal policies obtained from our POMDP model differ in several aspects from traditional policies that are based on a predefined PSA screening frequency and PSA threshold for biopsy referral. First, our policy uses the probability of being in state C. The probability is estimated from all prior PSA observations using Bayesian updating as the patient ages (see the section on Bayesian updating in the appendix for details). There is no fixed PSA test frequency; rather, PSA testing and biopsy occur according to a policy, defined by testing according to probability threshold, that maximizes long term expected rewards for the patient.

**Data Description**

We obtained the results of all PSA tests done in Olmsted County, Minnesota, from 1993 to 2005. A

total of 11,872 men underwent PSA testing during this time frame with a total of 50,589 PSA test results. The medical records linkage system of the Rochester Epidemiology Project<sup>17</sup> was then used to identify all patients who underwent a prostate biopsy or had a pathological diagnosis of prostate cancer during this same period of time. All health care providers in Olmsted County participate in the records linkage system, and more than 95% of Olmsted County residents receive their medical care in Olmsted County, implying that missed prostate biopsies and prostate cancer diagnoses are unlikely. We merged the PSA data with the clinical data to obtain a comprehensive longitudinal data set of PSA screening occurring in a fixed geographic population of men not subject to major referral biases. Because we focus on the screening policy for early detection, we do not consider PSA records after cancer treatment. We use the data set to estimate prostate cancer probabilities conditional on PSA level for a general population. Details of clinical and demographic characteristics of the screened cohort can be found in Table 1.

**Base Case Parameter Estimation**

Following is a summary of the model parameter estimates. First, we use our data set to estimate the probability of observing different PSA values conditional on the patients’ health states. This is represented by the information matrix defined earlier in the Methods section. (Note that Thompson and others<sup>18</sup> estimated the prostate cancer probability given PSA test results, which is related but not the same as what we need.) Because it is possible that some men with prostate cancer were never subjected to biopsy and therefore never diagnosed, the information matrix,  $Q_i(\ell_t|s_t)$ , is subject to bias. We used the methods proposed by Begg and Greenes<sup>19</sup> to correct for this bias. We use biopsy as the confirmative test; thus, we assume that patients who have positive biopsies are true cancer patients and those who have negative biopsy are true no cancer patients. We first separate the patients into different groups according to their PSA values ( $[0, 1)$ ,  $[1, 2.5)$ ,  $[2.5, 4)$ ,  $[4, 7)$ ,  $[7, 10)$ , and  $\geq 10$ ) and ages ( $[40, 50)$ ,  $[50, 60)$ ,  $[60, 70)$ ,  $[70, 80)$ , and  $\geq 80$ ). Within each group, we assume that patients without a confirmative test (biopsy) have the same probability of prostate cancer as patients who have had a confirmative test. The probability of having prostate cancer based on patients with confirmative tests is used to infer the cancer state of patients without confirmative tests.

**Table 1** Clinical and Demographic Characteristics of the Screened Cohort From Olmsted County, Minnesota

Population Size	11,872
Age, x (s)	63.0(12.7)
Race	
Caucasian	96%
Other	4%
PSA group, ng/mL	
0–1	5428
1–2.5	3657
2.5–4	1230
4–7	868
7–10	302
≥ 10	387
Outcomes	
Prostate biopsy	908
Prostate cancer diagnosis	628

The resulting information matrix is

$$Q_t(\ell_t|s_t) = \begin{pmatrix} 0.471 & 0.337 & 0.101 & 0.059 & 0.015 & 0.017 & 0 & 0 \\ 0.138 & 0.229 & 0.192 & 0.226 & 0.103 & 0.112 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & 1 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & 0 & 1 \end{pmatrix},$$

$$\forall t.$$

The rows of  $Q_t(\ell_t|s_t)$  correspond to states NC, C, T, and D, respectively; the columns correspond to PSA intervals  $[0, 1)$ ,  $[1, 2.5)$ ,  $[2.5, 4)$ ,  $[4, 7)$ ,  $[7, 10)$ ,  $[10, \infty)$ , T, and D, respectively.  $Q_t(\ell_t|s_t)$  is fixed for all the ages in this empirical study because our numerical experiments showed the differences in  $Q_t(\ell_t|s_t)$  with respect to age do not significantly influence the optimal policy.

The prostate cancer incidence rate,  $w_t$  (shown in Table 2), is calculated from the prevalence of prostate cancer at autopsy from the autopsy review study<sup>20</sup> assuming the annual prostate cancer incidence rate is fixed for each 10-year age interval.

In the absence of screening, we assume that patients are not detected with prostate cancer unless metastasis is discovered, in which case radical prostatectomy is no longer a good treatment option. Therefore, we assume patients in state C cannot transition to state T in the absence of screening. Patients in state C have higher death rate from prostate cancer. The prostate cancer death rate in the absence of screening,  $e_t$ , is approximated using the death rate of prostate cancer patients under conservative management.<sup>21</sup>

We assume that patients detected with prostate cancer are treated by prostatectomy. This is one of the most common forms of treatment.<sup>6,22</sup> Patients who enter the treatment state, T, receive expected rewards based on an aggregation of the 4 prostate cancer stages. To estimate the annual prostate cancer death rate excluding death from other causes for patients in state T,  $b_t$ , we estimated survival rates for the 4 prostate cancer stages using the Mayo Clinic Radical Prostatectomy Registry (MCRPR) and the Surveillance, Epidemiology and End Results (SEER) data<sup>23</sup> (see Figure 3 for details of data sources and values). In estimating the MCRPR transition rates after radical prostatectomy, all patients having undergone radical prostatectomy at the Mayo Clinic in the PSA era (1990–2005) were included. The patient population of 13,313 men was stratified into 3 TNM 2002-based stage groupings (Stage II, organ confined; Stage III, extraprostatic; Stage IV, lymph node positive). The probability of a radical prostatectomy patient being in 1 of the 3 stage groups was calculated from the pathological evaluation of the prostatectomy specimens obtained from each patient. The cumulative incidence (probability) of prostate cancer metastases and prostate cancer-specific mortality was calculated for each stage group using the competing risks estimator with nonprostate cancer death representing the competing risk.

We use the 4 cancer stages to calculate the total annual prostate cancer death rate for state T. The calculation is based on the mean death rate across the 4 prostate cancer stages at the time of detection. We estimated the annual death rates of organ-confined, extraprostatic, and lymph node-positive patients from the 5-, 10-, 15-, and 20-year death rates in Figure 3. (Letting  $s_t$  denote the  $t$  year death rate and solving 4 equations  $(1 - s_1)^t = 1 - s_t$  for  $t=5, 10, 15, 20$  for organ-confined, extraprostatic, and lymph node-positive patients.) We estimated annual death rate for metastases from the 5-year death rates for patients age  $<65$  and  $\geq 65$  from the SEER data. The aggregated death rate of T was then computed using the weighted average (weights correspond to the probabilities of being in different cancer stages upon detection in Figure 3) of the death rate of the 4 different cancer stages in Figure 3. Based on our estimates, the annual prostate cancer death rate in state T is  $b_t = 0.00672$  for  $t < 65$  and  $b_t = 0.00923$  for  $t \geq 65$  (note that the SEER data differentiate between patients younger and older than 65 years).

In our base case, we use a decrement of  $\mu = 0.05$  in the year of biopsy to estimate the disutility of biopsy. To our knowledge no estimates of utility

**Table 2** The Age-Specific Values of the Prostate Cancer Incidence Rate,  $w_t$

t	40 – 50	50 – 60	60 – 70	70 – 80	≥ 80
$w_t$	$2.32 \times 10^{-3}$	$4.70 \times 10^{-3}$	$7.02 \times 10^{-3}$	$6.17 \times 10^{-3}$	$1.17 \times 10^{-2}$




Figure 3 The detailed classification inside state T, where CD means the time at which cancer is detected; parameters in this figure are from the Mayo Clinic Radical Prostatectomy Registry and SEER.<sup>23</sup>

decrement exist yet for prostate biopsy; however, this estimate is consistent with similar choices of parameters for a recent breast cancer study<sup>24</sup> and a bladder cancer biopsy study.<sup>25</sup> In our base case, we assume that the utility decrement in years after treatment via prostatectomy is 0.145, which is the midpoint of 2 extremes reported in Bremner and others<sup>26</sup>: (a) the most severe (metastases), 0.24, and (b) minor symptoms (mild sexual dysfunction), 0.05. We assume a patient in state C, who has not been

detected with prostate cancer, has no reduction in quality of life.

The mortality rate from other causes,  $d_t$ , is age specific and based on the general mortality rate from Heron<sup>27</sup> minus the prostate cancer mortality rate from the National Cancer Institute.<sup>23</sup> Note that the National Cancer Institute<sup>23</sup> reports a single prostate cancer mortality rate for ages greater than 95 and Heron<sup>27</sup> reports a single all cause mortality rate for ages greater than 95. Therefore, we assume that  $d_t$  is

**Table 3** Parameters, Their Sources, and Specific Values Used in Our Base Case Analysis

Parameter	Description	Source	Value
$w_t$	Annual prostate cancer incidence rate	Ref. 23	Age specific
$d_t$	Annual death rate from other causes	Refs. 23, 27	Age specific
$b_t$	Annual prostate cancer death rate excluding death from other causes for patients in state T	Mayo Clinic Radical Prostatectomy Registry	Age specific
$e_t$	Annual prostate cancer death rate excluding death from other causes for patients in state C	Ref. 21	0.033
$f$	Biopsy detection rate for prostate cancer patients	Ref. 4	0.8
$\mu$	One-time utility decrement associated with biopsy	Ref. 24	0.05
$\varepsilon$	Annual utility decrement of living in state T	Ref. 26	0.145
$\beta$	Societal willingness to pay in U.S. dollars/QALY	Ref. 28	50,000
$c_p$	Cost of a PSA test in U.S. dollars	Ref. 29	37
$c_b$	Cost of a biopsy in U.S. dollars	Ref. 29	393
$c_t$	Cost of prostate cancer treatment in U.S. dollars	Ref. 22	17,226

QALY, quality-adjusted life year.

fixed after the age of 95. All other parameters and their sources are provided in Table 3.

## RESULTS

### Optimal Screening Policies

Base case results are provided in Figure 4. Figure 4a illustrates the optimal prostate cancer screening policy from the patient's perspective (maximize expected QALYs). PSA tests occur annually until the probability threshold for biopsy is 1. A threshold of 1 is interpreted as electing not to perform biopsy (and subsequent treatment) even if the patient is known to have prostate cancer with certainty. As the patient ages, the thresholds for PSA testing and biopsy increase. Thus, PSA testing and biopsy are more selective at older ages. The stopping time for PSA screening is observed to be age 76.

Figure 4b illustrates the optimal prostate cancer screening policy from the societal perspective (maximize the difference in expected rewards for QALYs and expected costs). The 2 criteria are weighted using a societal willingness to pay of  $\beta = \$50,000/\text{QALY}$ .<sup>28</sup> The stopping time of PSA screening is observed to be age 71. In contrast to the patient perspective, PSA testing is more selective at older ages. The threshold for biopsy is also higher than for the patient perspective.

### Benefits of Prostate Cancer Screening

We use a simulation model based on our partially observable Markov model to compare the optimal

policy to a traditional guideline of annual PSA screening with PSA threshold 4.0 ng/mL for biopsy. A sample size of 3,000,000 is used in the simulations to obtain the expected QALYs associated with the traditional guideline. From the patient's perspective, we estimate the benefit of prostate cancer screening based on the expected future QALYs for a 40-year-old patient starting with no prostate cancer. We compare the optimal policy versus (a) no screening and (b) the traditional guideline.

For our base case, the optimal screening policy has an average benefit of 0.131 QALYs compared with no screening, and 0.165 QALYs compared with the traditional guideline. Thus, the number needed to screen (NNS) to gain 1 additional QALY is 6. Note that the benefit is greater relative to the traditional guideline, implying the traditional guideline is worse than no screening at all. From the societal perspective, for our base case, with a societal willingness to pay of  $\beta = \$50,000$  U.S. dollars per QALY, males benefit an average of 0.110 QALYs compared with no screening and 0.161 QALYs compared with the traditional guideline.

### Sensitivity Analysis

We provide the results of 2 sensitivity analyses. The first, presented in Table 4, evaluated sensitivity to  $\mu$  and  $\varepsilon$ , the factors affecting QALYs. The second, presented in Table 5, evaluates sensitivity to the economic factors: costs and willingness to pay.

From Table 4 the benefit of screening is very sensitive to  $\mu$  and  $\varepsilon$ . The benefits of prostate cancer screening are most significant for cases in which  $\mu$




Figure 4 Optimal prostate cancer screening policies from the (A) patient and (B) societal perspectives. Lines denote thresholds for PSA testing and biopsy. If the patient's age and probability of having prostate cancer are in area B he is referred for biopsy; DB means defer biopsy referral until obtaining the PSA test result in the next decision epoch; DP means defer biopsy referral and the PSA test in the next decision epoch.

and  $\epsilon$  are minimized. From the patient perspective, the NNS ranges from 3.46 ( $\mu = 0.01$  and  $\epsilon = 0.05$ ) to 40 ( $\mu = 0.1$  and  $\epsilon = 0.24$ ). From the societal perspective the NNS ranges from 3.75 ( $\mu = 0.01$  and  $\epsilon = 0.05$ ) to 62.5 ( $\mu = 0.1$  and  $\epsilon = 0.24$ ). The stopping time of PSA screening is also presented in Table 4. Because it is rare to screen people older than 84 for prostate cancer, the prostate cancer incidence rate for patients older than 84 is underestimated. Therefore, we denote later stopping times as  $>84$ . From the patient perspective stopping time ranges from age 60 to 84 or older; from the societal perspective stopping time ranges from 57 to 84.

Table 5 presents results based on varying societal willingness to pay and the costs of PSA tests, biopsy, and treatment (it focuses on the societal perspective because it is the most affected by changes in cost and willingness to pay). Costs were most sensitive to willingness to pay, ranging from 583 U.S. dollars to 1411 U.S. dollars. Stopping times varied by as much as 2 years with respect to cost and by as much as 7 years with respect to willingness to pay.

**DISCUSSION**

The introduction of PSA screening for prostate cancer is responsible, in whole or in part, for a number of positive effects, including prostate cancer diagnoses made 5 to 10 years earlier than previously possible,<sup>30</sup> a reduction in the incidence of advanced stage prostate cancer,<sup>31,32</sup> and a reduction in prostate

cancer mortality.<sup>10</sup> However, PSA screening also has some downsides, including the cost of screening,<sup>29</sup> the possibility of false-positive tests leading to unnecessary prostate biopsy and anxiety,<sup>33</sup> and the overdiagnosis and overtreatment of prostate cancer.<sup>2,3</sup> It is widespread interest in determining whether better designed PSA screening protocols can reduce the downsides of PSA screening while continuing to bolster its benefits. Because of the difficulties of using randomized clinical trials, models such as ours are necessary for analyzing and comparing alternative PSA screening policies.<sup>14</sup>

Ross and others<sup>34</sup> reported on a simulation model to compare several alternative strategies (e.g., no screening, and screening intervals of 1, 2, and 5 y) based on performance measures including the number of PSA tests per 1000 men and prostate cancer deaths prevented. Like our study, their model is based on a Markov process for progression of the disease. They considered 2 competing criteria: prostate cancer deaths prevented per 1000 men and number of PSA tests per 1000 men. Etzioni and others<sup>31</sup> also used a simulation model to determine whether declines in advanced stage prostate cancer can be attributed to PSA screening. They concluded that PSA screening has contributed in part to declines in incidence and resulting mortality of prostate cancer.

Markov decision processes (MDP) have been applied to several complex medical decision paradigms including liver transplantation,<sup>35</sup> diabetes management,<sup>36</sup> and HIV treatment.<sup>37</sup> POMDP models, such as ours, are a special case of MDPs in

**Table 4** Sensitivity Analysis of the Expected Benefits of PSA Screening for 40-Year-Old Healthy Men for Different  $\epsilon$  and  $\mu$

$\epsilon$	$\mu$	Benefit Over No PSA Screening, QALYs/person	Benefit Over Traditional Guideline, QALYs/person	Screening Stopping Age
<b>Patient perspective</b>				
0.05	0.01	0.289	0.292 (0.277, 0.307)	> 84
	0.05	0.271	0.312 (0.297, 0.327)	> 84
	0.1	0.253	0.340 (0.325, 0.355)	> 84
<b>0.145</b>	0.01	0.148	0.151 (0.136, 0.166)	77
	<b>0.05</b>	<b>0.131</b>	<b>0.165 (0.150, 0.180)</b>	<b>76</b>
	0.1	0.116	0.204 (0.189, 0.219)	75
0.24	0.01	0.044	0.047 (0.031, 0.062)	61
	0.05	0.032	0.073 (0.058, 0.088)	60
	0.1	0.025	0.113 (0.098, 0.128)	60
<b>Societal perspective</b>				
0.05	0.01	0.267	0.270 (0.255, 0.286)	84
	0.05	0.244	0.285 (0.270, 0.300)	83
	0.1	0.224	0.312 (0.297, 0.327)	82
<b>0.145</b>	0.01	0.131	0.134 (0.119, 0.149)	71
	<b>0.05</b>	<b>0.110</b>	<b>0.161 (0.145, 0.176)</b>	<b>71</b>
	0.1	0.095	0.192 (0.177, 0.207)	70
0.24	0.01	0.034	0.044 (0.029, 0.060)	58
	0.05	0.022	0.063 (0.048, 0.078)	57
	0.1	0.016	0.104 (0.089, 0.119)	57

QALY, quality-adjusted life year. The optimal policy is compared with the case of no screening and the case of annual PSA tests with 4.0 ng/mL threshold for biopsy from both patient and societal perspectives. The latter perspective is based on a societal willingness to pay of  $\beta = 50,000$ . Because the expected QALYs of the traditional guideline are obtained by simulation, 95% confidence interval is presented in the parentheses. The base case is represented in bold.

**Table 5** Sensitivity Analysis of the Total Costs of the Optimal Policy and the Traditional Guideline for 40-Year-Old Healthy Men From the Societal Perspective for Varying  $\beta$  and Costs: Other Parameters Including  $\epsilon$  and  $\mu$  Are Set According to the Base Case

$\beta$	Costs	Cost of the Optimal Policy, U.S. \$/Person	Cost of the Traditional Guideline, U.S. \$/Person	Screening Stopping Age
250,000	-20%	957	764	74
	Base case	1185	956	74
	+20%	1411	1147	73
100,000	-20%	904	764	73
	Base case	1104	956	73
	+20%	1274	1147	72
<b>50,000</b>	-20%	768	764	71
	<b>Base case</b>	<b>882</b>	<b>956</b>	<b>71</b>
	+20%	989	1147	69
25,000	-20%	583	764	68
	Base case	642	956	67
	+20%	658	1147	65

which there is imperfect information about the patient’s health state; they can also be applied to medical decision making and we explore this possibility in the current study. Recently, Alagoz and others<sup>38</sup> provided a tutorial on the construction and evaluation of MDPs and POMDPs in medical

decision making. Hu and others<sup>39</sup> considered the problem of choosing an appropriate drug infusion plan for the administration of anesthesia. Hauskrecht and Fraser<sup>40</sup> applied a POMDP formulation to the problem of treating patients with ischemic heart disease, and Maillart and others<sup>41</sup> used

a partially observable Markov chain to study breast cancer screening policies using mammography.

Our study differs from the above referenced work in several respects. To our knowledge, ours is the first optimization study of prostate cancer screening that explicitly treats the imperfect nature of PSA tests and prostate biopsies over the course of a patient's lifetime. In contrast to simulation models for evaluating PSA screening policies,<sup>34</sup> we study an optimization model that seeks to maximize an explicit objective. We evaluate and compare 2 objectives for prostate cancer screening from both the patient and societal perspectives. We calibrate our model with a large population-based data set that includes all screening and treatment events. Other studies have used data sets derived from subsets of the total population, such as high-risk patients or patients participating in clinical trials, and these studies are therefore subject to significant selection bias.

Several insights can be drawn from the results of our POMDP model. We found that PSA testing and biopsy should be discontinued at older ages because competing mortality risks eventually dominate the risk of prostate cancer. For our baseline model, the optimal policy from the patient perspective suggests annual PSA screening until age 76, which is surprisingly close to the stopping time of age 75 recommended by the U.S. Preventive Services Task Force.<sup>11</sup> The optimal policy from the societal perspective suggests more selective PSA screening based on the patient's age and probability of having prostate cancer. It also suggests that all PSA screening should be stopped after age 71, independent of the probability of prostate cancer.

The PSA thresholds at which our model recommended performing prostate biopsy decreased with age from both the patient and societal perspectives, implying that younger patients should be screened more intensively than older patients. To gain perspective on the benefits at the population level, total annual benefits for the entire eligible U.S. population were estimated by multiplying the benefit per person by the 40-year-old male population estimated from the U.S. census.<sup>42</sup> From the patient perspective, the optimal policy yields an annual incremental benefit of 293,000 QALYs for the U.S. population. From the societal perspective the annual incremental benefit is 246,000 QALYs, based on a societal willingness to pay of 50,000 U.S. dollars per QALY.

Sensitivity analysis suggests the benefits of PSA screening from both patient and societal perspectives are highly dependent on the harm induced by prostate biopsy and prostate cancer treatment. This implies

that society might benefit from future studies that better estimate how harmful prostate biopsy and cancer treatment really are. Furthermore, from the sensitivity analysis, the traditional PSA screening guideline is worse than no screening at all for all the parameter settings from both patient and societal perspectives.

Our study estimates the benefit of using a patient's full PSA history and thus provides a more accurate estimate of the true information provided by PSA-based screening. Implementation of such policies based on a patient's probability of prostate cancer would require access to a patient's past PSA test results. Thus, our study provides an example of benefits that could be derived from standardized and easy-to-access electronic medical records.

There are some limitations of our study. Our estimates of disutilities are based on a sparse literature on QALYs for prostate cancer, biopsy, and treatment. Our assumptions reflect conservative estimates of the benefits of PSA screening. For instance, we do not discount quality of life for asymptomatic patients who become symptomatic. However, our assumptions were based on the best available data and we use sensitivity analysis to characterize variation with respect to these inputs. We do not consider other screening methods such as digital rectal examination (DRE) in our model. This is attributable in part to the lack of data concerning DRE in our population. Given the demographic makeup of the population in Olmsted County, Minnesota, our model was based on a largely Caucasian population. Future work based on a more diverse population could reveal insights about the role of race as a risk factor in prostate cancer screening decisions. Our model provides a foundation for these future studies.

## CONCLUSIONS

Unlike traditional PSA-threshold based policies, our model produces policies that depend on the probability of prostate cancer and the patient's complete history of PSA test results. Our results help to understand the gap between patient and societal perspectives on prostate cancer screening policy. Our results also demonstrate the relative sensitivity of policies to parameters that influence quality of life and encourage directions of future research to better understand patient utility decrements for screening and treatment. Finally, our results also shed light on the recent controversy over PSA testing by evaluating the benefits that may be derived from using the full range of PSA test results rather than a single observation.

**APPENDIX**  
**Model Parameters**

The parameters used to construct the state transition probability matrices and the rewards in our model are defined in Table 3.

**Transition Probabilities**

We denote the transition probability matrix given the decision to biopsy,  $B$ , as  $P_t(s_{t+1}|s_t, B)$ , consisting of elements  $p_t(s_{t+1}|s_t, B)$ ,  $\forall s_{t+1} \in S, s_t \in S$ , where the non-zero elements are

$$\begin{aligned} p_t(NC|NC, B) &= (1 - d_t)(1 - w_t), \\ p_t(C|NC, B) &= (1 - d_t)w_t, \\ p_t(D|NC, B) &= d_t, \\ p_t(C|C, B) &= (1 - f)(1 - d_t)(1 - e_t), \\ p_t(T|C, B) &= f(1 - b_t)(1 - d_t), \\ p_t(D|C, B) &= d_t + fb_t(1 - d_t) + e_t(1 - f)(1 - d_t), \\ p_t(T|T, B) &= (1 - d_t)(1 - b_t), \\ p_t(D|T, B) &= d_t + b_t(1 - d_t), \\ p_t(D|D, B) &= 1. \end{aligned}$$

We denote the transition probability matrix at epoch  $t$  given the decisions not to biopsy immediately,  $DB$  and  $DP$ , as  $P_t(s_{t+1}|s_t, DB)$  and  $P_t(s_{t+1}|s_t, DP)$  consisting of elements  $p_t(s_{t+1}|s_t, DB)$ ,  $\forall s_{t+1} \in S, s_t \in S$ , and  $p_t(s_{t+1}|s_t, DP)$ ,  $\forall s_{t+1} \in S, s_t \in S$ , where the non-zero elements are

$$\begin{aligned} p_t(NC|NC, DP) &= p_t(NC|NC, DB) = (1 - d_t)(1 - w_t), \\ p_t(C|NC, DP) &= p_t(C|NC, DB) = (1 - d_t)w_t, \\ p_t(D|NC, DP) &= p_t(D|NC, DB) = d_t, \\ p_t(C|C, DP) &= p_t(C|C, DB) = (1 - d_t)(1 - e_t), \\ p_t(D|C, DP) &= p_t(D|C, DB) = d_t + e_t(1 - d_t), \\ p_t(T|T, DP) &= p_t(T|T, DB) = (1 - d_t)(1 - b_t), \\ p_t(D|T, DP) &= p_t(D|T, DB) = d_t + b_t(1 - d_t), \\ p_t(D|D, DP) &= p_t(D|D, DB) = 1. \end{aligned}$$

Note that the last 3 elements of  $p_t(s_{t+1}|s_t, B)$ ,  $p_t(s_{t+1}|s_t, DB)$  and  $p_t(s_{t+1}|s_t, DP)$  are identical because they are independent of the decision. From this point forward, we write them as  $p_t(T|T)$ ,  $p_t(D|T)$ , and  $p_t(D|D)$ , respectively.

**Reward Function**

Following are the annual rewards associated with the societal perspective (note that the patient perspective is a special case in which cost  $c_p = c_b = c_t = 0$  and the willingness to pay  $\beta = \infty$ ). The rewards given the decision to biopsy,  $B$ , are

$$\begin{aligned} r_t(NC, B) &= \beta(1 - \mu) - c_b, \\ r_t(C, B) &= \beta(1 - \mu - \delta(1 - f) - f\varepsilon) - c_b - f \cdot c_t, \\ r_t(T) &= 1 - \varepsilon, \\ r_t(D) &= 0. \end{aligned}$$

We define the following rewards given the decision is  $DB$ :

$$\begin{aligned} r_t(NC, DB) &= \beta - c_p, \\ r_t(C, DB) &= \beta(1 - \delta) - c_p, \\ r_t(T) &= 1 - \varepsilon, \\ r_t(D) &= 0. \end{aligned}$$

The rewards given the decision is  $DP$  are

$$\begin{aligned} r_t(NC, DP) &= \beta, \\ r_t(C, DP) &= \beta(1 - \delta), \\ r_t(T) &= 1 - \varepsilon, \\ r_t(D) &= 0. \end{aligned}$$

The rewards defined above reflect the following assumptions. All the utility parameters,  $w_t$ ,  $d_t$ ,  $b_t$ ,  $e_t$ ,  $f$ ,  $\mu$ ,  $\delta$ , and  $\varepsilon$ , have values in  $[0, 1]$ . A patient with prostate cancer that has not been detected may suffer side effects that degrade their quality of life by  $\delta \geq 0$ . A patient who has a biopsy has his quality of life reduced by  $\mu$  in the year of biopsy. In other words,  $\mu$  reflects the reduction in quality of life due to the biopsy procedure

including factors such as pain, anxiety, and short-term procedure side effects such as infection. A patient who has a positive biopsy and is treated suffers a loss of  $\varepsilon$  QALYs for all future life years; that is,  $\varepsilon$  reflects reduced quality of life due to side effect of treatment. Note that we are implicitly assuming that the utility decrements,  $\mu$ ,  $\varepsilon$ ,  $\delta$ , are based on population averages, and the decision maker is risk neutral. The reward in QALYs are then translated into monetary values by multiplying by  $\beta$ .

### Bayesian Updating

Bayesian updating is used to revise the patient's belief state over time as PSA observations are obtained. Bayesian updates are defined by the following transformation of the belief state:

$$\pi_{t+1}(s_{t+1}) = \frac{q_{t+1}(\ell_{t+1}|s_{t+1}) \sum_{s_t \in S} p_t(s_{t+1}|s_t, a_t) \pi_t(s_t)}{\sum_{s_{t+1} \in S} q_{t+1}(\ell_{t+1}|s_{t+1}) \sum_{s_t \in S} p_t(s_{t+1}|s_t, a_t) \pi_t(s_t)},$$

where the posterior belief of being in state  $s_{t+1}$ ,  $\pi_{t+1}(s_{t+1})$ , the component of the vector  $\pi_{t+1}$ , is a function of PSA observation  $\ell_{t+1}$ , action  $a_t$  and the prior belief vector  $\pi_t$ . Thus, this equation provides a means to update the belief state of a patient based on their prior belief state and their most recent observed PSA interval. For instance, when the action is DP and the PSA test result falls into interval  $\ell_{t+1}$ , the posterior belief of having prostate cancer is

$$\pi_{t+1}(C) = \frac{q_{t+1}(\ell_{t+1}|C) \sum_{s_t \in S} p_t(C|s_t, a_t) \pi_t(s_t)}{\sum_{s_{t+1} \in S} q_{t+1}(\ell_{t+1}|s_{t+1}) \sum_{s_t \in S} p_t(s_{t+1}|s_t, a_t) \pi_t(s_t)}.$$

### Optimality Equation

Prostate cancer screening is a 2-stage decision problem. The optimality equations can be written as

$$v_t(\pi_t(C)) = \max\{R_t(\pi_t(C)), v_t(\pi_t(C), DB), v_t(\pi_t(C), DP)\}, \forall t, \forall \pi_t(C) \in [0, 1],$$

where  $v_t(\pi_t(C))$  is the expected future reward for a patient age  $t$  with probability of prostate cancer and  $\pi_t(C)$ ;  $v_t(\pi_t(C), DP)$  is the expected future reward given  $a_t = DP$  at decision epoch  $t$ , which can be written as:

$$v_t(\pi_t(C), DP) = r_t(\pi_t(C), DP) + v_{t+1}(\pi_{t+1}) p_t(\pi_{t+1}|\pi_t(C), DP);$$

$v_t(\pi_t(C), DB)$  is the expected future reward given  $a_t = DB$  at decision epoch  $t$ , which can be written as:

$$v_t(\pi_t(C), DB) = r_t(\pi_t(C), DB) + \sum_{\ell_{t+1} \in M} v_{t+1}(\pi_{t+1}) p_t(\ell_{t+1}|\pi_t(C), DB);$$

$R_t(\pi_t(C))$  is the expected future reward given  $a_t = B$  at decision epoch  $t$ , which can be written as:

$$R_t(\pi_t(C)) = (1 - \pi_t(C)) \bar{R}_t(NC) + \pi_t(C) ((1 - f) \bar{R}_t(C) + f \bar{R}_t(T)) - \beta \mu - c_b,$$

where  $\bar{R}_t(NC)$ ,  $\bar{R}_t(C)$ , and  $\bar{R}_t(T)$  denote the expected future rewards under the policy of never referring the patient for PSA tests and biopsy after age  $t$  for states  $NC$ ,  $C$ , and  $T$ , respectively, which can be written as:

$$\begin{aligned} \bar{R}_t(NC) &= r_t(NC, DP) + (p_t(NC|NC, DP) \bar{R}_{t+1}(NC) + p_t(C|NC, DP) \bar{R}_{t+1}(C)), \\ \bar{R}_t(C) &= r_t(C, DP) + p_t(C|C, DP) \bar{R}_{t+1}(C), \\ \bar{R}_t(T) &= r_t(T) + p_t(T|T) \bar{R}_{t+1}(T). \end{aligned}$$

### REFERENCES

- Holmstrom B, Johansson M, Bergh A, Stenman UH, Hallmans G, Stattin P. Prostate specific antigen for early detection of prostate cancer: longitudinal study. *Br Med J*. 2009;339:b3537.
- Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. *J Natl Cancer Inst*. 2002;94(13):981–90.
- Welch HG, Black WC. Overdiagnosis in cancer. *J Natl Cancer Inst*. 2010;102(9):605–13. Available from: URL: <http://dx.doi.org/10.1093/jnci/djq099>
- Haas GP, Delongchamps NB, Jones RF, et al. Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. *J Natl Cancer Inst*. 2007;99:1484–9.
- Woolf SH, Rothenich SF. Screening for prostate cancer: the roles of science, policy, and opinion in determining what is best for patients. *Annu Rev Med*. 1999;50:207–21.
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer Early Detection V.2.; 2007. Online booklet available at [www.nccn.org](http://www.nccn.org).
- Etzioni R, Cha R, Cowen ME. Serial prostate specific antigen screening for prostate cancer: a computer model evaluates competing strategies. *J Urol*. 1999;162:741–8.

8. American Urological Association. Prostate Specific Antigen Best Practice Statement: 2009 Update. Linthicum, MD: American Urological Association Education and Research; 2009.
9. Woolf SH. Screening for prostate cancer with prostate-specific antigen: an examination of the evidence. *N Engl J Med*. 1995; 333(21):1401–5.
10. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. *N Engl J Med*. 2009;360(13):1320–8. Available from: URL: <http://dx.doi.org/10.1056/NEJMoa0810084>
11. US Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2008;149(3):185–91.
12. Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. *N Engl J Med*. 2009;360(13):1310–9. Available from: URL: <http://dx.doi.org/10.1056/NEJMoa0810696>
13. Pinsky PF, Black A, Kramer BS, Miller A, Prorok PC, Berg C. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. *Clin Trials*. 2010 June. Available from: URL: <http://dx.doi.org/10.1177/1740774510374091>
14. Schroder FH, Roobol MJ. ERSPC and PLCO prostate cancer screening studies: what are the differences? *Eur Urol*. 2010 March. Available from: URL: <http://dx.doi.org/10.1016/j.eururo.2010.03.033>
15. Zhang J, Denton BT, Balasubramanian H, Shah ND, Inman BA. Optimization of Prostate Biopsy Referral Decisions. Working Paper Raleigh, NC: North Carolina State University; 2009.
16. Lovejoy WS. A survey of algorithmic methods for partially observed Markov decision processes. *Ann Oper Res*. 1991;28:47–66.
17. Melton LJ. History of the Rochester Epidemiology Project. *Mayo Clin Proc*. 1996;71(3):266–74.
18. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. *J Natl Cancer Inst*. 2006;98(8):529–34.
19. Begg CB, Greenes RA. Assessment of diagnostic tests when disease verification is subject to selection bias. *Biometrics*. 1983; 39(1):207–15.
20. Bubendorf L, Schöpfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. *Hum Pathol*. 2000;31(5):578–83.
21. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. *J Am Med Assoc*. 2005;293(17):2095–101.
22. Burkhardt JH, Litwin MS, Rose CM, et al. Comparing the costs of radiation therapy and radical prostatectomy for the initial treatment of early-stage prostate cancer. *J Clin Oncol*. 2002;20(12):2869–75.
23. National Cancer Institute. Surveillance epidemiology and end results [database]; 2008. Available from: URL: <http://seer.cancer.gov/>
24. Chhatwal J, Alagoz O, Burnside ES. Optimal breast biopsy decision-making based on mammographic features and demographic factors. *Oper Res*. 2010;58(6):1577–91.
25. Kulkarni GS, Finelli A, Fleshner NE, Jewett MAS, Lopushinsky SR, Alibhai SMH. Optimal management of high-risk T1G3 bladder cancer: a decision analysis. *PLoS Med*. 2007;4(9):e284. Available from: URL: <http://dx.doi.org/10.1371/journal.pmed.0040284>
26. Bremner KE, Chong CAKY, Tomlinson G, Alibhai SMH, Krahn MD. A review and meta-analysis of prostate cancer utilities. *Med Decis Making*. 2007;27:288–98.
27. Heron M. Deaths: Leading causes for 2004. *National Vital Statistics Reports*. 2007;56(5):1–96.
28. Rascati KL. The \$64,000 question—what is a quality-adjusted life-year worth? *Clin Ther*. 2006;26(7):1042–3.
29. Ekwueme DU, Stroud LA, Chen Y. Cost analysis of screening for, diagnosing, and staging prostate cancer based on a systematic review of published studies. *Prev Chronic Dis*. 2007;4(4):1–17.
30. Draisma G, Etzioni R, Tsodikov A, et al. Lead time and over-diagnosis in prostate-specific antigen screening: importance of methods and context. *J Natl Cancer Inst*. 2009;101(6):374–383. Available from: URL: <http://dx.doi.org/10.1093/jnci/djp001>
31. Etzioni R, Gulati R, Falcon S, Penson DF. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. *Med Decis Making*. 2008;28:323–31.
32. Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer—results from a prospective, population-based randomized controlled trial. *Eur Urol*. 2007;51(3):659–664. Available from: URL: <http://dx.doi.org/10.1016/j.eururo.2006.07.012>
33. McNaughton-Collins M, Fowler FJ, Caubet JF, et al. Psychological effects of a suspicious prostate cancer screening test followed by a benign biopsy result. *Am J Med*. 2004;117(10):719–25. Available from: URL: <http://dx.doi.org/10.1016/j.amjmed.2004.06.036>
34. Ross KS, Carter HB, Pearson JD, Guess HA. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. *J Am Med Assoc*. 2000;284(11):1399–405.
35. Alagoz O, Maillart LM, Schaefer AJ, Roberts MS. The optimal timing of living-donor liver transplantation. *Manage Sci*. 2004; 50(10):1420–30.
36. Denton BT, Kurt M, Shah ND, Bryant SC, Smith SA. Optimizing the start time of statin therapy for patients with diabetes. *Med Decis Making*. 2009;29(3):351–67.
37. Shechter SM, Bryce CL, Alagoz O, et al. A clinically based discrete event simulation of end-stage liver disease and the organ allocation process. *Med Decis Making*. 2005;25(2):199–209.
38. Alagoz O, Hsu H, Schaefer AJ, Roberts MS. Markov decision processes: a tool for sequential decision making under uncertainty. *Med Decis Making*. 2010;30(4):474–83. Available from: URL: <http://dx.doi.org/10.1177/0272989X09353194>
39. Hu C, Lovejoy WS, Shafer SL. Comparison of some suboptimal control policies in medical drug therapy. *Oper Res*. 1993;44: 696–709.
40. Hauskrecht M, Fraser H. Planning treatment of ischemic heart disease with partially observable Markov decision processes. *Artif Intell Med*. 2000;18:221–44.
41. Maillart LM, Ivy JS, Ransom S, Diehl K. Assessing dynamic breast cancer screening policies. *Oper Res*. 2008;56(6):1411–27.
42. US Census Bureau. Annual estimates of the population by five-year age groups and sex for the United States: April 1, 2000 to July 1, 2006 (NC-EST2006-01) [database on the Internet]; 2006. Available from: URL: <http://www.census.gov/popest/national/asrh/NC-EST2006-sa.html>